title: The Chinese First-Episode Schizophrenia Trial: background and study design.
abstract: Schizophrenia is a complex illness with unknown aetiology and pathogenesis. Currently, a considerable number of patients with schizophrenia do not receive standardised and systematic treatment in China. In the past years, many controlled trials have been conducted in chronic schizophrenia. In contrast, research on first-episode schizophrenia is lacking. This paper describes the background and design of the Chinese First-Episode Schizophrenia Trial project--a multicentre, randomised, open-label clinical trial. A total of 600 first-episode schizophrenia patients were randomly divided into 3 groups and treated with risperidone, aripiprazole, and olanzapine for 1 year. During the study period, only 1 medication change of the 3 antipsychotic medications was allowed.
authors.affiliation: Peking University Sixth Hospital, Peking University Institute of Mental Health, Key Laboratory of Mental Health, Ministry of Health (Peking University), Beijing, China.
authors.forename: X
authors.initials: X
authors.lastname: Han
authors.affiliation: Peking University Sixth Hospital, Peking University Institute of Mental Health, Key Laboratory of Mental Health, Ministry of Health (Peking University), Beijing, China.
authors.forename: Y B
authors.initials: YB
authors.lastname: Yuan
authors.affiliation: Peking University Sixth Hospital, Peking University Institute of Mental Health, Key Laboratory of Mental Health, Ministry of Health (Peking University), Beijing, China.
authors.forename: X
authors.initials: X
authors.lastname: Yu
authors.affiliation: Mental Health Institute, the Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
authors.forename: J P
authors.initials: JP
authors.lastname: Zhao
authors.affiliation: Beijing Anding Hospital, Capital Medical University, Beijing, China.
authors.forename: C Y
authors.initials: CY
authors.lastname: Wang
authors.affiliation: Shanghai Mental Health Center, Shanghai Jiaotong University School of Medicine, Shanghai, China.
authors.forename: Z
authors.initials: Z
authors.lastname: Lu
authors.affiliation: Center for Biological Psychiatry, Beijing Hui-Long-Guan Hospital, Beijing, China.
authors.forename: F D
authors.initials: FD
authors.lastname: Yang
authors.affiliation: Mental Health Center, West China Hospital, Sichuan University, Chengdu, Sichuan province, China.
authors.forename: H
authors.initials: H
authors.lastname: Dong
authors.affiliation: The George Institute for Global Health at Peking University Health Science Center, Beijing, China.
authors.forename: Y F
authors.initials: YF
authors.lastname: Wu
authors.affiliation: The University of Notre Dame Australia / Marian Centre, Perth, Australia.
authors.forename: G S
authors.initials: GS
authors.lastname: Ungvari
authors.affiliation: Faculty of Health Sciences, University of Macau, Macao, China.
authors.forename: Y T
authors.initials: YT
authors.lastname: Xiang
authors.affiliation: Department of Psychiatry, The Chinese University of Hong Kong, Hong Kong SAR, China.
authors.forename: H F K
authors.initials: HF
authors.lastname: Chiu
mesh_terms: D000293:Adolescent; D000328:Adult; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D000068180:Aripiprazole; D001569:Benzodiazepines / Q000627:therapeutic use*; D002681:China; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009483:Neuropsychological Tests; D000077152:Olanzapine; D010879:Piperazines / Q000627:therapeutic use*; D015363:Quinolones / Q000627:therapeutic use*; D012107:Research Design; D018967:Risperidone / Q000627:therapeutic use*; D012559:Schizophrenia / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D014150:Antipsychotic Agents; D010879:Piperazines; D015363:Quinolones; D001569:Benzodiazepines; D000068180:Aripiprazole; D018967:Risperidone; D000077152:Olanzapine
keywords: Antipsychotic agents; Clinical trial; Schizophrenia